CNBX Acquires A Controlling Interest In Cancer Immunotherapy Developer
CNBX Pharmaceuticals Inc. (OTCQB: CNBX) has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd. The TaGeza research team remains committed to the company, and co-founder professor Benjamin Dekel (MD, PhD) will continue to serve as the company's chief scient
